The Pneumococcal Vaccines Market is predicted to reach US$ by 2030 from US$ 8.3 billion in 2021, and to grow at a CAGR of 5.20% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Vaccine Type (Pneumococcal Conjugate Vaccine (PCV), Pneumococcal Polysaccharide Vaccine (PPSV/PPV)), by Product Type (Prevnar 13, Synflorix, Pneumovax 23)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotech Ltd., Pfizer Inc., Sanofi S.A., Walvax Biotechnology Co. Ltd, CSL Ltd., Serum Institute of India Pvt. Ltd., and Talley Group Ltd.
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Pneumococcal Vaccines - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Pneumococcal Vaccines - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Pneumococcal Vaccines - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Pneumococcal Vaccines - ANALYSIS & FORECAST, BY REGION
North America Pneumococcal Vaccines
1. North America Pneumococcal Vaccines , by Country
1. US
2. Canada
1. North America Pneumococcal Vaccines , by Product
2. North America Pneumococcal Vaccines , by Type
3. North America Pneumococcal Vaccines , by Gender
4. North America Pneumococcal Vaccines , by Sales Channel
3. Europe Pneumococcal Vaccines
1. Europe Pneumococcal Vaccines , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Pneumococcal Vaccines , by Product
3. Europe Pneumococcal Vaccines , by Type
4. Europe Pneumococcal Vaccines , by Gender
5. Europe Pneumococcal Vaccines , by Sales Channel
4. Asia Pacific Pneumococcal Vaccines
1. Asia Pacific Pneumococcal Vaccines , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Pneumococcal Vaccines , by product
3. Asia Pacific Pneumococcal Vaccines , by Type
4. Asia Pacific Pneumococcal Vaccines , by Gender
5. Asia Pacific Pneumococcal Vaccines , by Sales Channel
5. Rest of the World Pneumococcal Vaccines
1. Rest of the World Pneumococcal Vaccines , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Pneumococcal Vaccines , by Product
3. Rest of the World Pneumococcal Vaccines , by Type
4. Rest of the World Pneumococcal Vaccines , by Gender
5. Rest of the World Pneumococcal Vaccines , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 39
The Vaccines Isothermal Boxes Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufactu...
Asia Pacific preventive vaccines market will grow by 7.9% annually with a total addressable market cap of $217.46 billion over 2023-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for p...
Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines s...
North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for pre...
Global preventive vaccines market will reach $120.07 billion by 2032, growing by 6.4% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as ...
The global Human Rabies Vaccines market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in thi...
The global Recombinant Vector Vaccines market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players ...
The global DTaP and Tdap Vaccines market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in th...
The global Japanese Encephalitis Vaccines market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market playe...
The global Nasal Spray Flu Vaccines market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in ...